LL-37
LL-37 (Cathelicidin)
The body's innate antibiotic and immune coordinator
How it works
LL-37 disrupts bacterial membranes via amphipathic helix formation and acts as an immune modulator. It recruits neutrophils, monocytes, and T-cells to sites of infection, and can neutralize bacterial endotoxin (LPS) to prevent septic shock.
What the research explores
In published research, LL-37 has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.
- Broad-spectrum antimicrobial activity (bacteria, fungi, viruses)
- Stimulates wound healing and angiogenesis
- Modulates innate and adaptive immune responses
- Neutralizes bacterial endotoxin
- Anti-biofilm properties
- Promotes epithelial cell migration and proliferation
LL-37 is the only cathelicidin in humans and represents a key bridge between innate and adaptive immunity. Clinical trials are ongoing for infected chronic wounds and cystic fibrosis lung infections.
Adverse events & gaps
At high concentrations, may cause cell membrane disruption in host cells. Therapeutic window is well-characterized.
Stay Informed on
Peptide Research
Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.
No spam. Unsubscribe at any time.